Reimbursed medication adherence enhancing interventions in 12 european countries: Current state of the art and future challenges

Background: Medication non-adherence jeopardises the effectiveness of chronic therapies and negatively affects financial sustainability of healthcare systems. Available medication adherence-enhancing interventions (MAEIs) are utilised infrequently, and even more rarely reimbursed. The aim of this pa...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2022-08, Vol.13, p.944829-944829
Main Authors: Kardas, Przemysław, Bago, Martina, Barnestein-Fonseca, Pilar, Garuolienė, Kristina, Granas, Anne Gerd, Gregório, João, Hadžiabdić, Maja Ortner, Kostalova, Barbora, Leiva-Fernández, Francisca, Lewek, Pawel, Mala-Ladova, Katerina, Schneider, Marie Paule, van Boven, Job F. M., Volmer, Daisy, Ziampara, Ioli, Ágh, Tamás
Format: Article
Language:English
Subjects:
Europe
interventions
medication adherence
non-adherence
persistence
Pharmacology
reimbursement
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Medication non-adherence jeopardises the effectiveness of chronic therapies and negatively affects financial sustainability of healthcare systems. Available medication adherence-enhancing interventions (MAEIs) are utilised infrequently, and even more rarely reimbursed. The aim of this paper was to review reimbursed MAEIs across selected European countries. Methods: Data on reimbursed MAEIs were collected from European countries at the ENABLE Cost Action expert meeting in September 2021. The identified MAEIs were analysed and clustered according to their characteristics, direct vs. indirect relation to adherence, and the targeted adherence phase. Results: Out of 12 contributing countries, 10 reported reimbursed MAEIs, 28 in total, of which 20 were identified as MAEIs targeting adherence directly. Reimbursed MAEIs were most often performed by either doctors ( n = 6), nurses ( n = 6), or pharmacists ( n = 3). The most common types of MAEIs were education ( n = 6), medication regimen management ( n = 5), and adherence monitoring feedback ( n = 4). Only seven reimbursed MAEIs were technology-mediated, whereas 11 addressed two interlinked phases of medication adherence, i.e. , implementation and persistence. Conclusion: Our review highlights the scarcity of reimbursed MAEIs across the selected European countries, and calls for their more frequent use and reimbursement.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.944829